Johnson & Johnson‘s (NYSE:JNJ) Codman Neuro said last week it picked up Pulsar Vascular, which produces the PulseRider device for treating brain aneurysms, for an undisclosed amount.
The PulseRider is designed to shore up the blood vessels around wide-necked aneurysms at or near a bifurcation of the basilar tip or carotid terminus and facilitate the implantation of an embolization coil, without obstructing blood flow through the vessels, according to the company’s website.
Codman Neuro said the acquisition will complement its portfolio of products covering hemorrhagic and ischemic stroke.
“There is a significant unmet medical need for the treatment of complex bifurcation aneurysms which pose a high risk to the patient. Pulsar Vascular Inc.’s technology design is a great example of how innovation is driving improved outcomes for patients facing a condition that could have profound impact on their lives. Working together, we will leverage our proven market expertise and strong commercial footprint to bring this technology to many more clinicians worldwide,” J&J medical devices cardiovascular & specialty solutions group chair Shlomi Nachman said in a press release.
Codman Neuro was previously the exclusive distributor of the device in Europe, where it won CE Mark approval in 2013. Pulsar Vascular said it has compelted a US investigational device exemption clinical trial, and is awaiting humanitarian device exemption approval.
In August, Codman Neuro said it inked an exclusive U.S. and European distribution deal with InNeuroCo for its intermediate catheters designed for the minimally invasive treatment of hemorrhagic stroke.
Florida-based InNueroCo develops and manufactures neurovascular products designed to treat hemorrhagic stroke. The distro deal includes InNeuroCo’s intermediate catheter and super distal access device. The intermediate catheter has FDA and CE Mark approval, Codman Neuro said, while the super distal access device is pending FDA 510(k) clearance.
